Elanco Animal Health Incorporated Selling, General and Administrative Expense
Elanco Animal Health Incorporated (ELAN) reported Selling, General and Administrative Expense of $449.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- Elanco Animal Health Incorporated selling, general and administrative expense for the quarter ending 2026-06-30 was $449.00M, a 12.25% increase year-over-year.
- Elanco Animal Health Incorporated selling, general and administrative expense for the quarter ending 2026-03-31 was $381.00M, a 11.73% increase year-over-year.
- Elanco Animal Health Incorporated selling, general and administrative expense for the quarter ending 2025-12-31 was $338.00M, a 12.67% increase year-over-year.
- Elanco Animal Health Incorporated selling, general and administrative expense for the quarter ending 2025-09-30 was $351.00M, a 8.67% increase year-over-year.
- Elanco Animal Health Incorporated selling, general and administrative expense for fiscal 2025 was $1.43B, a 8.83% increase from fiscal 2024.
- Elanco Animal Health Incorporated selling, general and administrative expense for fiscal 2024 was $1.31B, a 2.26% increase from fiscal 2023.
- Elanco Animal Health Incorporated selling, general and administrative expense for fiscal 2023 was $1.28B, a 1.58% increase from fiscal 2022.
- Elanco Animal Health Incorporated selling, general and administrative expense for fiscal 2022 was $1.26B, a 9.84% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $449.00M 10-Q · filed 2026-08-05 | $830.00M 10-Q · filed 2026-08-05 | $1.17B derived: sum of 3 quarters · filed 2026-08-05 | $1.52B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $381.00M 10-Q · filed 2026-05-06 | $719.00M derived: sum of 2 quarters · filed 2026-05-06 | $1.07B derived: sum of 3 quarters · filed 2026-05-06 | $1.47B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $338.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $689.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.09B derived: sum of 3 quarters · filed 2026-08-05 | $1.43B 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $351.00M 10-Q · filed 2025-11-05 | $751.00M derived: sum of 2 quarters · filed 2026-08-05 | $1.09B 10-Q · filed 2025-11-05 | $1.39B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $400.00M 10-Q · filed 2026-08-05 | $741.00M 10-Q · filed 2026-08-05 | $1.04B derived: sum of 3 quarters · filed 2026-08-05 | $1.36B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $341.00M 10-Q · filed 2026-05-06 | $641.00M derived: sum of 2 quarters · filed 2026-05-06 | $964.00M derived: sum of 3 quarters · filed 2026-05-06 | $1.32B derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $300.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $623.00M derived: sum of 2 quarters · filed 2026-02-24 | $977.00M derived: sum of 3 quarters · filed 2026-02-24 | $1.31B 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $323.00M 10-Q · filed 2025-11-05 | $677.00M derived: sum of 2 quarters · filed 2025-11-05 | $1.01B 10-Q · filed 2025-11-05 | $1.31B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $354.00M 10-Q · filed 2025-08-07 | $691.00M 10-Q · filed 2025-08-07 | $983.00M derived: sum of 3 quarters · filed 2026-02-24 | $1.30B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $337.00M 10-Q · filed 2025-05-07 | $629.00M derived: sum of 2 quarters · filed 2026-02-24 | $942.00M derived: sum of 3 quarters · filed 2026-02-24 | $1.29B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $292.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $605.00M derived: sum of 2 quarters · filed 2026-02-24 | $958.00M derived: sum of 3 quarters · filed 2026-02-24 | $1.28B 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $313.00M 10-Q · filed 2024-11-07 | $666.00M derived: sum of 2 quarters · filed 2024-11-07 | $993.00M 10-Q · filed 2024-11-07 | $1.29B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $353.00M 10-Q · filed 2024-08-08 | $680.00M 10-Q · filed 2024-08-08 | $982.00M derived: sum of 3 quarters · filed 2025-02-25 | $1.28B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $327.00M 10-Q · filed 2024-05-08 | $629.00M derived: sum of 2 quarters · filed 2025-02-25 | $927.00M derived: sum of 3 quarters · filed 2025-02-25 | $1.27B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $302.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $600.00M derived: sum of 2 quarters · filed 2025-02-25 | $943.00M derived: sum of 3 quarters · filed 2025-02-25 | $1.26B 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $298.00M 10-Q · filed 2023-11-07 | $641.00M derived: sum of 2 quarters · filed 2023-11-07 | $963.00M 10-Q · filed 2023-11-07 | $961.00M 10-Q · filed 2022-11-08 | $1.29B derived: sum of 4 quarters · filed 2023-11-07 | |||
| 2022-06-30 | $343.00M 10-Q · filed 2023-08-07 | $666.00M 10-Q · filed 2023-08-07 | $663.00M 10-Q · filed 2022-08-08 | $993.00M derived: sum of 3 quarters · filed 2023-08-07 | $1.33B derived: sum of 4 quarters · filed 2023-08-07 | |||
| 2022-03-31 | $323.00M 10-Q · filed 2023-05-09 | $320.00M 10-Q · filed 2022-05-09 | $650.00M derived: sum of 2 quarters · filed 2023-05-09 | $992.00M derived: sum of 3 quarters · filed 2023-05-09 | $1.38B derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $327.00M 10-K · filed 2023-03-01 | $669.00M derived: sum of 2 quarters · filed 2023-03-01 | $1.05B derived: sum of 3 quarters · filed 2023-03-01 | $1.40B 10-K · filed 2024-02-26 | $1.40B 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $342.00M 10-K · filed 2023-03-01 | $727.00M derived: sum of 2 quarters · filed 2023-03-01 | $1.07B 10-Q · filed 2022-11-08 | $1.45B derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $385.00M 10-K · filed 2023-03-01 | $733.00M 10-Q · filed 2022-08-08 | $1.11B derived: sum of 3 quarters · filed 2023-03-01 | $1.39B derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $349.00M 10-K · filed 2023-03-01 | $348.00M 10-Q · filed 2021-05-07 | $723.00M derived: sum of 2 quarters · filed 2023-03-01 | $1.00B derived: sum of 3 quarters · filed 2023-03-01 | $1.16B derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | $374.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $652.00M derived: sum of 2 quarters · filed 2023-03-01 | $815.00M derived: sum of 3 quarters · filed 2023-03-01 | $997.00M 10-K · filed 2023-03-01 | $996.60M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $278.00M 10-Q · filed 2021-11-05 | $277.70M 10-Q · filed 2020-11-06 | $441.00M derived: sum of 2 quarters · filed 2021-11-05 | $623.00M 10-Q · filed 2021-11-05 | $622.50M 10-Q · filed 2020-11-06 | $808.70M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $163.00M 10-Q · filed 2021-08-09 | $162.80M 10-Q · filed 2020-07-30 | $345.00M 10-Q · filed 2021-08-09 | $344.80M 10-Q · filed 2020-07-30 | $530.70M derived: sum of 3 quarters · filed 2022-02-28 | $723.00M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | $182.00M 10-Q · filed 2021-05-07 | $367.70M derived: sum of 2 quarters · filed 2022-02-28 | $560.00M derived: sum of 3 quarters · filed 2022-02-28 | $760.90M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $185.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $378.00M derived: sum of 2 quarters · filed 2022-02-28 | $578.90M derived: sum of 3 quarters · filed 2022-02-28 | $760.00M 10-K · filed 2022-02-28 | $760.20M 10-K · filed 2020-02-28 | |||
| 2019-09-30 | $192.30M 10-Q · filed 2020-11-06 | $393.20M derived: sum of 2 quarters · filed 2020-11-06 | $574.30M 10-Q · filed 2020-11-06 | $759.40M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $200.90M 10-Q · filed 2020-07-30 | $382.00M 10-Q · filed 2020-07-30 | $567.10M derived: sum of 3 quarters · filed 2021-03-01 | $746.10M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $181.10M 10-Q · filed 2020-05-07 | $366.20M derived: sum of 2 quarters · filed 2021-03-01 | $545.20M derived: sum of 3 quarters · filed 2021-03-01 | $736.30M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $185.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $364.10M derived: sum of 2 quarters · filed 2021-03-01 | $555.20M derived: sum of 3 quarters · filed 2021-03-01 | $735.20M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $179.00M 10-Q · filed 2019-11-08 | $370.10M derived: sum of 2 quarters · filed 2019-11-08 | $550.10M 10-Q · filed 2019-11-08 | $746.90M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $191.10M 10-Q · filed 2019-08-13 | $371.10M 10-Q · filed 2019-08-13 | $567.90M derived: sum of 3 quarters · filed 2020-02-28 | $762.60M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | $180.00M 10-Q · filed 2019-05-14 | $376.80M derived: sum of 2 quarters · filed 2020-02-28 | $571.50M derived: sum of 3 quarters · filed 2020-02-28 | |||||
| 2017-12-31 | $196.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $391.50M derived: sum of 2 quarters · filed 2020-02-28 | $779.80M 10-K · filed 2020-02-28 | |||||
| 2017-09-30 | $194.70M 10-Q · filed 2018-11-08 | $583.00M 10-Q · filed 2018-11-08 | ||||||
| 2016-12-31 | $784.80M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |